Cancer Research AACR Membership Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drevs, J.
Right arrow Articles by Marmé, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drevs, J.
Right arrow Articles by Marmé, D.
[Cancer Research 62, 4015-4022, July 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging1

Joachim Drevs2, Ralph Müller-Driver, Christine Wittig, Stefan Fuxius, Norbert Esser, Harald Hugenschmidt, Moritz A. Konerding, Peter R. Allegrini, Jeanette Wood, Jürgen Hennig, Clemens Unger and Dieter Marmé

Department of Medical Oncology [J. D., R. M-D., C. W., S. F., C. U.] and Institute of Molecular Oncology [N. E., H. H., D. M.], Tumor Biology Center, 79106 Freiburg, Germany; Department of Diagnostic Radiology, Section of Medical Physics, Albert-Ludwigs-University Hospital, 79106 Freiburg, Germany [J. H.]; Department of Anatomy, Johannes Gutenberg-University, 55099 Mainz, Germany [M. A. K.]; and Oncology Therapeutic Area and Core Technology Area, Novartis Pharma AG, Basel, Switzerland [P. R. A., J. W.]

Antiangiogenic therapy is a promising new strategy of inhibiting tumor growthand formation of metastases. Recently, a number of compounds with different effects on tumor endothelial cells have entered clinical trials and revealed the need for diagnostic methods to detect their biological activity. Dynamic enhanced magnetic resonance imaging (dyMRI) is used in most clinical trials with antiangiogenic active compounds. We evaluated this method by using PTK787/ZK 222584, a specific inhibitor of the VEGF-receptor tyrosine kinases, which showed antitumoral and antiangiogenic activity in a murine renal cell carcinoma (RENCA) model. After intrarenal application of RENCA cells, mice developed a primary tumor and metastases to the lung and abdominal lymph nodes. After daily oral therapy for 21 days with either PTK787/ZK 222584 at a dose of 50 mg/kg or vehicle, primary tumors of all animals were analyzed by dyMRI. Gadolinium-DOTA (Dotarem) was used as a contrast agent to detect vessel permeability and contrast agent extravasation, whereas intravascular iron oxide nanoparticles (Endorem) were used to detect partial tumor blood volume. Additionally, vessel density, architecture, diameter, and blood flow velocity were investigated by appropriate methods.

Surprisingly, no changes in extravasation occurred under treatment with PTK787/ZK 222584 as compared with the control group, whereas a significant decrease in vessel permeability occurred. Furthermore, an increase in partial blood volume was found in the PTK787/ZK 222584-treated group, although vessel density was reduced as seen by histology. Using the corrosion cast technique, reduction in vessel density was significant but not very pronounced and predominantly attributable to the loss of microvessels only. This finding correlated with a shift to large vessel diameters in the primary tumors of PTK787/ZK 222584-treated animals and with reduction of blood flow velocity in the tumor feeding renal artery. From these findings, we conclude that the treatment with PTK787/ZK 222584 primarily reduces the number of tumor microvessels, accompanied by a hemodynamic dilation of the remaining vessels. This dilation could influence the result of dyMRI such that no change in extravasation or even an increase in partial tumor blood volume could be observed.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. A. Lane, J. M. Wood, P. M.J. McSheehy, P. R. Allegrini, A. Boulay, J. Brueggen, A. Littlewood-Evans, S.-M. Maira, G. Martiny-Baron, C. R. Schnell, et al.
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Clin. Cancer Res., March 1, 2009; 15(5): 1612 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
V. Goh, S. Halligan, F. Daley, D. M. Wellsted, T. Guenther, and C. I. Bartram
Colorectal Tumor Vascularity: Quantitative Assessment with Multidetector CT--Do Tumor Perfusion Measurements Reflect Angiogenesis?
Radiology, November 1, 2008; 249(2): 510 - 517.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, T. Karrison, E. Manchen, M. Mitchell, M. J. Ratain, and W. M. Stadler
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
J. Clin. Oncol., October 1, 2008; 26(28): 4572 - 4578.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Hlushchuk, O. Riesterer, O. Baum, J. Wood, G. Gruber, M. Pruschy, and V. Djonov
Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation
Am. J. Pathol., October 1, 2008; 173(4): 1173 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. de Bazelaire, D. C. Alsop, D. George, I. Pedrosa, Y. Wang, M. D. Michaelson, and N. M. Rofsky
Magnetic Resonance Imaging-Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma
Clin. Cancer Res., September 1, 2008; 14(17): 5548 - 5554.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. K. Rathmell, W. M. Stadler, and B. I. Rini
Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, J. Harder, H. Blum, J. Robertson, J. M. Jurgensmeier, et al.
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol., July 20, 2007; 25(21): 3045 - 3054.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Mannheim, D. Versari, E. Daghini, M. Gossl, O. Galili, A. Chade, V. S. Rajkumar, E. L. Ritman, L. O. Lerman, and A. Lerman
Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2449 - H2458.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Thomas, T Trarbach, C Bartel, D Laurent, A Henry, M Poethig, J Wang, E Masson, W Steward, U Vanhoefer, et al.
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
Ann. Onc., April 1, 2007; 18(4): 782 - 788.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. J. O'Dwyer
The Present and Future of Angiogenesis-Directed Treatments of Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 992 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al.
KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties.
Cancer Res., September 15, 2006; 66(18): 9134 - 9142.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Mol. Cancer Ther., August 1, 2006; 5(8): 1950 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al.
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. R. Kim, A. Yudina, J. Figueiredo, W. Reichardt, D. Hu-Lowe, A. Petrovsky, H. W. Kang, D. Torres, U. Mahmood, R. Weissleder, et al.
Detection of Early Antiangiogenic Effects in Human Colon Adenocarcinoma Xenografts: In vivo Changes of Tumor Blood Volume in Response to Experimental VEGFR Tyrosine Kinase Inhibitor
Cancer Res., October 15, 2005; 65(20): 9253 - 9260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Marzola, A. Degrassi, L. Calderan, P. Farace, E. Nicolato, C. Crescimanno, M. Sandri, A. Giusti, E. Pesenti, A. Terron, et al.
Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma
Clin. Cancer Res., August 15, 2005; 11(16): 5827 - 5832.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. L. Thomas, B. Morgan, M. A. Horsfield, A. Higginson, A. Kay, L. Lee, E. Masson, M. Puccio-Pick, D. Laurent, and W. P. Steward
Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer
J. Clin. Oncol., June 20, 2005; 23(18): 4162 - 4171.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Drevs, U. Zirrgiebel, C. I. M. Schmidt-Gersbach, K. Mross, M. Medinger, L. Lee, J. Pinheiro, J. Wood, A. L. Thomas, C. Unger, et al.
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
Ann. Onc., April 1, 2005; 16(4): 558 - 565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al.
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Beghein, P. Sonveaux, J. De Wever, P. Martinive, V. Gregoire, O. Feron, and B. Gallez
Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Clin. Cancer Res., January 15, 2005; 11(2): 743 - 750.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
V. Mastyugin, E. McWhinnie, M. Labow, and F. Buxton
A Quantitative High-Throughput Endothelial Cell Migration Assay
J Biomol Screen, December 1, 2004; 9(8): 712 - 718.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
P. Traxler, P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, et al.
AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity
Cancer Res., July 15, 2004; 64(14): 4931 - 4941.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey
Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts
Cancer Res., July 1, 2004; 64(13): 4601 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al.
Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts
Am. J. Pathol., July 1, 2004; 165(1): 35 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Evelhoch, P. M. LoRusso, Z. He, Z. DelProposto, L. Polin, T. H. Corbett, P. Langmuir, C. Wheeler, A. Stone, J. Leadbetter, et al.
Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
Clin. Cancer Res., June 1, 2004; 10(11): 3650 - 3657.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M. Kamat, T. Karashima, D. W. Davis, L. Lashinger, M. Bar-Eli, R. Millikan, Y. Shen, C. P. N. Dinney, and D. J. McConkey
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo
Mol. Cancer Ther., March 1, 2004; 3(3): 279 - 290.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
J. Schoenberger, D. Grimm, P. Kossmehl, M. Infanger, E. Kurth, and C. Eilles
Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study
Endocrinology, March 1, 2004; 145(3): 1031 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. van Hensbergen, H. J. Broxterman, S. Rana, P. J. van Diest, M. C. A. Duyndam, K. Hoekman, H. M. Pinedo, and E. Boven
Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts
Clin. Cancer Res., February 1, 2004; 10(3): 1180 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Marzola, A. Degrassi, L. Calderan, P. Farace, C. Crescimanno, E. Nicolato, A. Giusti, E. Pesenti, A. Terron, A. Sbarbati, et al.
In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model
Clin. Cancer Res., January 15, 2004; 10(2): 739 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A R Padhani
MRI for assessing antivascular cancer treatments
Br. J. Radiol., December 1, 2003; 76(suppl_1): S60 - S80.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Beebe, J. P. Jani, E. Knauth, P. Goodwin, C. Higdon, A. M. Rossi, E. Emerson, M. Finkelstein, E. Floyd, S. Harriman, et al.
Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy
Cancer Res., November 1, 2003; 63(21): 7301 - 7309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al.
CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
Cancer Res., September 15, 2003; 63(18): 5978 - 5991.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.